221 related articles for article (PubMed ID: 30444526)
1. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
[TBL] [Abstract][Full Text] [Related]
2. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
3. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
Bernard B; Muralidhar V; Chen YH; Sridhar SS; Mitchell EP; Pettaway CA; Carducci MA; Nguyen PL; Sweeney CJ
Cancer; 2017 May; 123(9):1536-1544. PubMed ID: 28055108
[TBL] [Abstract][Full Text] [Related]
4. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
5. Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
Lichtensztajn DY; Leppert JT; Brooks JD; Shah SA; Sieh W; Chung BI; Gomez SL; Cheng I
J Natl Compr Canc Netw; 2018 Nov; 16(11):1353-1360. PubMed ID: 30442735
[No Abstract] [Full Text] [Related]
6. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
8. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study.
Lycken M; Garmo H; Adolfsson J; Stattin P; Holmberg L; Bill-Axelson A
Eur J Cancer; 2014 Jul; 50(10):1789-1798. PubMed ID: 24736041
[TBL] [Abstract][Full Text] [Related]
9. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
Cheung DC; Alibhai SMH; Martin LJ; Komisarenko M; Dharma C; Warde P; Sridhar SS; Fleshner NE; Kulkarni GS; Finelli A
J Urol; 2021 Oct; 206(4):933-941. PubMed ID: 34032504
[TBL] [Abstract][Full Text] [Related]
10. Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States).
Morris CR; Snipes KP; Schlag R; Wright WE
Cancer Causes Control; 1999 Dec; 10(6):503-11. PubMed ID: 10616820
[TBL] [Abstract][Full Text] [Related]
11. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Schmidt AL; Tucker MD; Bakouny Z; Labaki C; Hsu CY; Shyr Y; Armstrong AJ; Beer TM; Bijjula RR; Bilen MA; Connell CF; Dawsey SJ; Faller B; Gao X; Gartrell BA; Gill D; Gulati S; Halabi S; Hwang C; Joshi M; Khaki AR; Menon H; Morris MJ; Puc M; Russell KB; Shah NJ; Sharifi N; Shaya J; Schweizer MT; Steinharter J; Wulff-Burchfield EM; Xu W; Zhu J; Mishra S; Grivas P; Rini BI; Warner JL; Zhang T; Choueiri TK; Gupta S; McKay RR
JAMA Netw Open; 2021 Nov; 4(11):e2134330. PubMed ID: 34767021
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.
Lin CC; Gray PJ; Jemal A; Efstathiou JA
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25957435
[TBL] [Abstract][Full Text] [Related]
13. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.
Gilbert SM; Kuo YF; Shahinian VB
Urol Oncol; 2011; 29(6):647-53. PubMed ID: 19926311
[TBL] [Abstract][Full Text] [Related]
14. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Philippou YA; Kuntz GM; Konety BR; Gupta S; Lamb AD; Dahm P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012816. PubMed ID: 30320443
[TBL] [Abstract][Full Text] [Related]
15. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care.
Freedman RA; Virgo KS; He Y; Pavluck AL; Winer EP; Ward EM; Keating NL
Cancer; 2011 Jan; 117(1):180-9. PubMed ID: 20939011
[TBL] [Abstract][Full Text] [Related]
16. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer.
Bagley AF; Anscher MS; Choi S; Frank SJ; Hoffman KE; Kuban DA; McGuire SE; Nguyen QN; Chapin B; Aparicio A; Pezzi TA; Smith GL; Smith BD; Hess K; Tang C
JAMA Netw Open; 2020 Mar; 3(3):e201255. PubMed ID: 32191331
[TBL] [Abstract][Full Text] [Related]
17. Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.
Suresh T; Sharma J; Goel S; Kovac E; Gao Q; Gartrell B
Clin Genitourin Cancer; 2019 Apr; 17(2):139-144. PubMed ID: 30655076
[TBL] [Abstract][Full Text] [Related]
18. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
19. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
[TBL] [Abstract][Full Text] [Related]
20. Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer.
Muralidhar V; Catalano PJ; Reznor G; Mahal BA; Choueiri TK; Sweeney CJ; Martin NE; Beard CJ; Chen YW; Nezolosky MD; Hoffman KE; Feng FY; Trinh QD; Nguyen PL
J Natl Compr Canc Netw; 2016 Apr; 14(4):421-8. PubMed ID: 27059190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
